Associated Disease Details
| Disease ID: | I13 |
| DO ID: | 3146 |
| Disease Name: | Lipid metabolism disorder |
| Definition: | An inherited metabolic disorder that involves the creation and degradation of lipids. http://en.wikipedia.org/wiki/Lipid_metabolism |
| Synonyms: | Hypertriglyceridemia; hypertriglyceridaemia; Hypercholesterolemia; Dyslipidemia; Hyperlipidemia, Familial Combined; Hyperlipidemias; fatty acid metabolism disorder; Familial hypercholesterolemia - heterozygous; Familial hypercholesterolemia - homozygous; Hypercholesterolemia; |
| Class: | disease of metabolism/ inherited metabolic disorder |
| Related Drugs: | Acipimox; Atorvastatin; Bezafibrate; Cholestyramine; Ezetimibe; Fenofibrate; Fish oil; Gemcabene; Gemfibrozil; Levothyroxine; Lovaza; Niacin; OMACOR; Omega 3 PUFA; Resmetirom; Rosuvastatin; Pemafibrate; |
| Mechanism: | Alterations in hepatic lipid and lipoprotein metabolism are major contributing factors to the increased CVD risk in NAFLD patients, and many promising NASH therapies in development also improve dyslipidemia in clinical trials. |
| Reference (PMIDs): | 33010471 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D013 | Aramchol | Chemical drug | DB11860 | SCD-1 | Enhance lipid metabolism | Under clinical trials | Details |
| D018 | Aspirin | Chemical drug | DB00945 | AKR1C1 inhibitor; PCNA downregulator | Enhance lipid metabolism | Under clinical trials | Details |
| D020 | Atorvastatin | Chemical drug | DB01076 | DPP4 inhibitor; AHR agonist; HDAC2 inhibitor; NR1I3 ligand | Enhance lipid metabolism | Under clinical trials | Details |
| D030 | Bergamot | Biological drug | DB14335 | -- | Enhance lipid metabolism | Under clinical trials | Details |
| D040 | BIO89-100 | Biological drug | -- | FGF21 analog | Improve insulin resistance; Enhance lipid metabolism | Under clinical trials | Details |
| D046 | Pegbelfermin | Biological drug | DB15365 | FGF21 analog | Improve insulin resistance; Enhance lipid metabolism; Anti-fibrosis | Under clinical trials | Details |
| D062 | Carnitine complex | Supplement | DB00583 | SLC22A4; SLC22A5; CRAT; MPO | -- | Under clinical trials | Details |
| D075 | Choline | Supplement | DB00122 | PLD2 product of; PLD1 product of | -- | Under clinical trials | Details |
| D078 | Cilofexor | Chemical drug | DB15168 | FXR agonist | Enhance lipid metabolism | Under clinical trials | Details |
| D117 | EDP-305 | Chemical drug | -- | FXR agonist | Enhance lipid metabolism | Under clinical trials | Details |
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
|---|---|---|---|---|---|---|
| R0088 | DB00227 | approved; investigational | small molecule | Lovastatin | Therapeutic strategy associated | Details |
| R0164 | DB00481 | approved; investigational | small molecule | Raloxifene | Therapeutic strategy associated | Details |
| R0227 | DB00641 | approved | small molecule | Simvastatin | Therapeutic strategy associated | Details |
| R1067 | DB06641 | investigational | small molecule | Perifosine | Therapeutic strategy associated | Details |
| R1096 | DB06778 | approved | small molecule | Cupric sulfate | Therapeutic strategy associated | Details |
| R1312 | DB09462 | approved; investigational | small molecule | Glycerin | Target associated | Details |
| R1338 | DB11117 | approved; investigational | small molecule | Undecylenic acid | Therapeutic strategy associated | Details |
| R1427 | DB12007 | experimental | small molecule | Isoflavone | Therapeutic strategy associated | Details |
| R1547 | DB14960 | approved | biotech | Somatrogon | Therapeutic strategy associated | Details |
| R1559 | DB15354 | approved; investigational | biotech | Evinacumab | Indication associated | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00007 | 35256601 | Cell Death Discov | LncRNA MEG3 up-regulates SIRT6 by ubiquitinating EZH2 and alleviates nonalcoholic fatty liver disease. | Details |
| A00022 | 35251469 | Oxid Med Cell Longev | Farnesoid X Receptor Deficiency Induces Hepatic Lipid and Glucose Metabolism Disorder via Regulation of Pyruvate Dehydrogenase Kinase 4. | Details |
| A00030 | 35250593 | Front Pharmacol | Combined Use of Bicyclol and Berberine Alleviates Mouse Nonalcoholic Fatty Liver Disease. | Details |
| A00044 | 35246007 | Bioengineered | Quantitative proteomics analysis based on tandem mass tag labeling coupled with labeling coupled with liquid chromatography-tandem mass spectrometry discovers the effect of silibinin on non-alcoholic fatty liver disease in mice. | Details |
| A00055 | 35240510 | Biochem Biophys Res Commun | Inulin activates FXR-FGF15 signaling and further increases bile acids excretion in non-alcoholic fatty liver disease mice. | Details |
| A00056 | 35240344 | Cell Mol Gastroenterol Hepatol | Activation of Liver mTORC1 Protects Against NASH via Dual Regulation of VLDL-TAG Secretion and De Novo Lipogenesis. | Details |
| A00092 | 35222799 | Oxid Med Cell Longev | 4-Octyl Itaconate Prevents Free Fatty Acid-Induced Lipid Metabolism Disorder through Activating Nrf2-AMPK Signaling Pathway in Hepatocytes. | Details |
| A00094 | 35222044 | Front Pharmacol | Antibiotic Disruption of the Gut Microbiota Enhances the Murine Hepatic Dysfunction Associated With a High-Salt Diet. | Details |
| A00096 | 35220997 | Discov Med | Farnesoid X Receptor as a Promising Therapeutic Target for Nonalcoholic Fatty Liver Disease (NAFLD) and the Current Development of Its Agonists. | Details |
| A00106 | 35217953 | Environ Sci Pollut Res Int | Environmental exposure to low-dose perfluorohexanesulfonate promotes obesity and non-alcoholic fatty liver disease in mice fed a high-fat diet. | Details |
| A00121 | 35213002 | Methods Mol Biol | Analysis of the Sphingolipidome in NAFLD. | Details |
| A00135 | 35212985 | Methods Mol Biol | Histopathological Diagnosis of Nonalcoholic Steatohepatitis (NASH). | Details |
| A00136 | 35212984 | Methods Mol Biol | Measurement of Hepatic Lipids. | Details |
| A00174 | 35198905 | iScience | Deletion of RNF186 expression suppresses diet-induced hepatic steatosis by regulating insulin activity. | Details |
| A00177 | 35197460 | Nat Commun | Kindlin-2 haploinsufficiency protects against fatty liver by targeting Foxo1 in mice. | Details |
| A00183 | 35195377 | Minerva Endocrinol (Torino) | Inflammation is associated with impairment of oxidative status, carbohydrate and lipid metabolism in type 2 diabetes complicated by non-alcoholic fatty liver disease. | Details |
| A00188 | 35192934 | Mol Ther | Dysregulated m6A modification promotes lipogenesis and development of non-alcoholic fatty liver disease and hepatocellular carcinoma. | Details |
| A00205 | 35187676 | J Food Biochem | Chitosan oligosaccharide attenuates hepatic steatosis in HepG2 cells via the activation of AMP-activated protein kinase. | Details |
| A00209 | 35185113 | J Pediatr Gastroenterol Nutr | Comparison of the Lipidomic Signature of Fatty Liver in Children and Adults: A Cross-Sectional Study. | Details |
| A00214 | 35182330 | Mol Cell Biochem | Menin regulates lipid deposition in mouse hepatocytes via interacting with transcription factor FoxO1. | Details |